B

Brickell Biotech Inc
F:VCC2

Watchlist Manager
Brickell Biotech Inc
F:VCC2
Watchlist
Price: 0.1344 EUR 30.61%
Market Cap: 16m EUR

Operating Margin
Brickell Biotech Inc

-310.2%
Current
-3 808%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-310.2%
=
Operating Profit
-21.5m
/
Revenue
6.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Brickell Biotech Inc
F:VCC2
16m EUR
-310%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
334.3B USD
30%
US
Amgen Inc
NASDAQ:AMGN
160.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
119.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD
-5%

Brickell Biotech Inc
Glance View

Market Cap
16m EUR
Industry
Biotechnology

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.

VCC2 Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-310.2%
=
Operating Profit
-21.5m
/
Revenue
6.9m
What is the Operating Margin of Brickell Biotech Inc?

Based on Brickell Biotech Inc's most recent financial statements, the company has Operating Margin of -310.2%.

Back to Top